Revolutionary Liquid Biopsy Test Receives FDA Breakthrough Status for Mold Infections

Zepto Life Technology's FDA Breakthrough Designation

Zepto Life Technology has achieved a significant milestone with the announcement that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its innovative test, the FungiFlex® Mold Panel. This liquid biopsy test stands at the forefront of diagnostic technology, designed specifically to assist in identifying invasive mold infections by detecting fungal cell-free DNA directly from plasma samples.

The FungiFlex® Mold Panel is currently accessible for physician orders through Zepto Life Technology’s CLIA-certified laboratory as a Laboratory Developed Test (LDT). This development comes at a crucial time, as invasive mold infections represent a challenging area in the medical field, particularly affecting immunocompromised patients who are at higher risk. The diagnostic process for these infections is notably complex, often involving multiple diagnostic modalities like imaging, microbiology, histopathology, and serologic testing, making organism-level identification particularly tough and critical.

The game-changing capability of the FungiFlex® Mold Panel lies in its ability to detect and identify clinically relevant mold pathogens, such as Aspergillus, Mucorales, Fusarium, and Scedosporium/Lomentospora directly from the blood plasma. This advancement promises to significantly improve clinicians' ability to diagnose infections that can lead to serious health complications if left undiagnosed.

Hannah Zhang, CEO of Zepto Life Technology, expressed her sentiments on this revolutionary achievement, stating, "One of the most frustrating realities in invasive fungal infections is that clinicians are often forced to make critical treatment decisions without knowing exactly which organism is causing disease. Our goal has always been to provide actionable organism-level information from a simple plasma sample. We believe targeted liquid biopsy testing has the potential to fundamentally change how these infections are diagnosed."

The FDA’s Breakthrough Devices Program is designed to accelerate the introduction of technologies that could transform the diagnosis or treatment of life-threatening or severely debilitating diseases. The recognition of the FungiFlex® Mold Panel underscores its potential to meet significant unmet needs in diagnosing invasive mold infections, bringing much-needed advancements to patient care.

About Zepto Life Technology

Zepto Life Technology specializes in molecular diagnostics, focusing on developing targeted liquid biopsy tests for infectious diseases. Utilizing proprietary Giant Magnetoresistance (GMR) biosensor technology, the company is committed to enabling precise detection and identification of pathogens directly from blood samples. Starting with invasive fungal infections, the Zepto MDx platform will broaden its reach to other infections in the future.

For those interested in learning more about clinical testing services or opportunities for collaboration, detailed information can be found on their website at ZeptoLife.com. With the increasing burden of invasive mold infections, Zepto Life Technology stands poised to make a significant impact in the field of diagnostics.